News Sage rejects Biogen takeover and launches review Sage Therapeutics has unanimously rejected Biogen's acquisition offer of around $469 million, saying it "significantly undervalues" the company.
News US/EU regulators start review of Biogen's high-dose Spinraza Biogen's new high-dose version of SMA drug Spinraza has started regulatory reviews - but can it help return the drug to growth?
News Sage sues Biogen after unsolicited takeover bid Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal.
News FDA sets August date for subcutaneous Leqembi decision FDA has started its review of an autoinjector version of Eisai and Biogen's Alzheimer's drug Leqembi that could allow patients to be dosed at home.
News Biogen offers to buy out wilting Sage for $442 million Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae.
News Eisai, Biogen eye 2025 approval for Leqembi autoinjector Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on
News UK project addresses capacity issue in CGT manufacturing A UK consortium has been set up to tackle a major issue in the development of cell and gene therapies (CGT) – a lack of manufacturing capacity.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face